Aspirin Effectiveness Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-04-30

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aspirin is an effective medicine for prevention of heart attacks in patients with coronary artery disease and works by preventing clots from forming. In previous studies aspirin has been found to be ineffective in between 2% and 65% of patients but none of these studies have looked specifically at coronary artery disease patients in Ireland. This study is being done to identify the percentage of patients in Ireland whose aspirin is not working effectively and help identify factors that could be used to target interventions to increase aspirin's effectiveness in Irish patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Coronary Artery Disease Aspirin Secondary Prevention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CAD patients

Representative sample of coronary artery disease patients receiving aspirin therapy for secondary prevention

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years or older
* Patients with documented coronary artery disease
* Current treatment with any dose of aspirin daily for a minimum of 3 months
* Able to provide written informed consent based on competent mental status

Exclusion Criteria

* Myocardial infarction, unstable angina or stroke during the preceding three months
* Platelet count \<125,000/mm
* Known haematological disorders
* Active malignancy on current chemotherapy or a recent diagnosis of cancer

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof Dermot Kenny

Prof. Dermot Kenny

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Prof. Dermot Kenny, MB, BCh, BAO, MD

Role: PRINCIPAL_INVESTIGATOR

Royal College of Surgeons, Ireland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beaumont Hospital

Dublin, Dublin, Ireland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Ireland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mary C De Voe, RN

Role: CONTACT

Phone: +353-21 4901442

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

INFACTs2010-001

Identifier Type: -

Identifier Source: org_study_id